Category - Executive Moves

Executive Moves

Sigyn Therapeutics strengthens board with 3 appointments

Sigyn Therapeutics (OTCQB:SIGY) appointed Richa Nand, Jim Dorst, and Christopher Wetzel to its board, effective Oct. 10, 2022. “As we transition toward the next phase of our clinical endeavors, it is an opportune...

October 4, 2022

Executive Moves

Paul Brennan steps down as CEO of NervGen

Paul Brennan Paul Brennan is stepping down as president, CEO and a director of NervGen Pharma (OTCQX:NGENF; TSXV:NGEN), effective immediately. The board appointed current executive chairman, Bill Radvak, as interim CEO...

September 23, 2022

Executive Moves

Verséa Holdings names Rob Sambursky as president to lead ophthalmic expansion

Verséa Holdings appointed Rob Sambursky, M.D., as president to support its corporate strategy and operations as well as lead the company’s expansion into the ophthalmic market. Verséa recently launched a new business...

August 16, 2022

Executive Moves

Titan Pharma names new CEO, expands board

Titan Pharmaceuticals (NASDAQ:TTNP) appointed Activist Investing’s David Lazar as interim chairman and CEO, with a mandate to lead Titan’s continuing review of strategic alternatives. He succeeds Marc Rubin, M.D...

August 16, 2022

Executive Moves

Enzo Biochem appoints Matthew Kupferberg as general counsel

Enzo Biochem (NYSE:ENZ) named Matthew Kupferberg as the company’s in-house general counsel. He was most recently general counsel, chief compliance officer and privacy officer of Digital Medical Technologies, a...

August 3, 2022

Executive Moves

DURECT names Timothy Papp as CFO

DURECT (NASDAQ:DRRX) appointed Timothy Papp as chief financial officer to direct and oversee all financial and capital markets activities, including accounting, financial reporting, financial planning and analysis...

July 5, 2022

Executive Moves

Zymeworks names Paul Moore as CSO

Zymeworks (NYSE:ZYME) is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as chief scientific officer, reporting directly to the CEO, effective July 18. Dr. Moore brings more than 25...

June 28, 2022

Executive Moves

Hepion adds accomplished biopharmaceutical executives Anand Reddi and Dr. Kaouthar Lbiati to board

Anand Reddi, M.S. Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its board of directors, effective immediately. “Mr. Reddi and Dr. Lbiati have a remarkable wealth...

June 28, 2022

Executive Moves

Hepion names accomplished life sciences veteran Launa Aspeslet as COO

Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Launa Aspeslet, Ph.D., RAC, as chief operating officer to support the company’s rencofilstat clinical program. A versatile C-level executive with more than 25 years of...

June 14, 2022

Executive Moves

Soricimed names scientific, academic leader Dr. Rodney Ouellette to SAB

Rodney Ouellette Soricimed Biopharma appointed one of Atlantic Canada’s leading cancer researchers, Rodney Ouellette, M.D. and Ph.D., to its scientific advisory board. “Rodney has dedicated his life’s work...

June 2, 2022

Category - Executive Moves

Sigyn Therapeutics strengthens board with 3 appointments

Paul Brennan steps down as CEO of NervGen

Verséa Holdings names Rob Sambursky as president to lead ophthalmic expansion

Titan Pharma names new CEO, expands board

Enzo Biochem appoints Matthew Kupferberg as general counsel

DURECT names Timothy Papp as CFO

Zymeworks names Paul Moore as CSO

Hepion adds accomplished biopharmaceutical executives Anand Reddi and Dr. Kaouthar Lbiati to board

Hepion names accomplished life sciences veteran Launa Aspeslet as COO

Soricimed names scientific, academic leader Dr. Rodney Ouellette to SAB

General

More